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Abstract Over the past decade, a large number of strat-
egies and technologies have been developed to reduce heart
failure progression. Among these, cardiac tissue engineer-
ing is one of the most promising. Aim of this study is to
develop a 3D scaffold to treat cardiac failure. A new
three-block copolymer, obtained from d-valerolactone and
polyoxyethylene, was synthesised under high vacuum
without catalyst. Copolymer/gelatine blends were micro-
fabricated to obtain a ECM-like geometry. Structures were
studied under morphological, mechanical, degradation and
biological aspects. To prevent left ventricular remodelling,
constructs were biofunctionalises with molecularly
imprinted nanoparticles towards the matrix metallopro-
teinase MMP-9. Results showed that materials are able to
reproduce the ECM structure with high resolution,
mechanical properties were in the order of MPa similar to
those of the native myocardium and cell viability was
verified. Nanoparticles showed the capability to rebind
MMP-9 (specific rebinding 18.67) and to be permanently
immobilised on the scaffold surface.
1 Introduction
One of the major causes of morbidity and mortality in the
industrialized world is myocardial infarction. In the most
severe cases the only possible treatments, such as
mechanical support based on left ventricular assistance
devices or cardiac transplantation, present important limi-
tations. For this, there is an urgent interest in the identifi-
cation of new strategies able to treat efficiently cardiac
pathology. A promising method is myocardial tissue engi-
neering where a scaffold can provide mechanical support to
damaged tissues and mainly instructs stem cell, both seeded
and in situ recruited, towards a correct morphogenesis of
cardiac tissue [1]. A crucial problem in myocardial tissue
engineering is that cells have to be inserted in tissue-engi-
neered devices. Although cardiomyocytes are the principal
component of the cardiac tissue, endothelial cells, fibro-
blasts, smooth muscle cells, neural cells, and leukocytes
comprise about 70% of the total cell number in the working
myocardium. A possible solution can be the use of stem
cells or the insertion of cardiomyocytes [2]. The identifi-
cation of a suitable cell source for tissue-engineered myo-
cardial patches has been a severe challenge for many years.
Indeed, allogenic cells are easy to obtain but could cause
immune suppression; autologous cells do not show immu-
nologic issues but are more difficult to obtain and expand in
cell culture [3]. A great variety of polymeric materials,
including synthetic or natural polymers and hybrid materi-
als, has been explored [4]. The last class also comprised
bioartificial materials, considered interesting because they
can combine together the best properties of both compo-
nents, mainly in terms of biocompatibility [5–7]. The basic
concept is that, anticipating at molecular level the interac-
tion between synthetic and natural components, it is pos-
sible to foresee a better integration with the natural tissue in
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respect to an artificial material, as verified for a large range
of polymeric systems able to mimic the extra-cellular
matrix (ECM) of different tissues such as bone and myo-
cardium [8, 9]. The optimal scaffold to engineer cardiac
muscle tissue has not yet been found because of needs for
satisfy the large repertory of requirements that a system,
designed to substitute structure and function of cardiac
ECM, must possess but recent papers conclude that research
can lead to find it in a short time [4, 10, 11]. Basic scaffold
requirements are biocompatibility, biodegradability, and
mechanical properties with a great compliance toward the
natural tissue. Moreover, porosity and micro architecture of
the scaffold are additional aspects to stimulate cell migra-
tion, growth, and vascularisation as well as provide nutri-
tional conditions for cells. One approach relies on attempts
to mimic the micro architecture of tissues and the micro-
environment around cells within the body [12–14]. The
development of scaffolds with controlled architecture and
specific surface topography, obtained through several
techniques such as selective laser sintering [15, 16] and soft
lithography [14], have been already described in literature.
Recently the authors prepared and characterised three-
dimensional microfabricated and bioartificial scaffolds
through soft lithography able to mimic the cardiac ECM
architecture [17].
Finally, an engineered construct has to be biomimetic,
stimulating precise reactions at a molecular level to direct
cell behaviour in terms of adhesion, differentiation, stem
cell recruitment, thanks to the presence of specific bio-
chemical and/or topological signalling at nano-scale level
[18]. To mimic the native tissue structures nanotechnolo-
gies can be merged with biomaterials [19]. Our research
group proposed for the first time molecular imprinting (MI)
as a new nanotechnology for the preparation of advanced
synthetic structures supporting cell adhesion and prolifer-
ation [20]. The MI technique allows obtaining synthetic
polymers, named molecularly imprinted polymers (MIPs),
capable to bind selectively a specific substance (template)
[21–23]. The main applications of MIPs include analytical
separation, artificial immuno-mimetic, antibody-mimetic
systems, and biomimetic sensors; in recent years, our
research aimed at developing novel applications of MIPs
with regard to biomaterials and tissue engineering [24–26].
The use of MIPs in tissue engineering improves the scaf-
fold performances adding complementary and selective
sites towards specific peptide sequences present in the
extra-cellular proteins. It can increase cell adhesion and
growth, as well as stem cell recruitment.
Preliminary in vitro cell culture tests demonstrated the
ability of functionalized materials with imprinted nano-
particles towards both fibronectin GRGDS and laminin
YIGSR sequence to promote cell adhesion, proliferation,
and differentiation [27, 28].
Poly(ester–ether–ester) tri-block copolymers have been
proposed as bioresorbable materials since many years [29,
30]. Since the not-catalysed synthesis was developed in our
laboratories [31–33], these copolymers were tested for cell
adhesion and proliferation and cytotoxicity [34, 35], as
well as for cytocompatibility and hemocompatibility [36,
37]. In vitro degradation of the copolymers, both in the
presence and in the absence of cells, was also tested [38].
Results showed that degradation products did not alter
endothelial metabolism [39] and modulated the endothelin
release by human umbilical vein endothelial cells, with no
significant alteration of the vasoconstrictor-vasodilator
balance [40]. Recently, microspheres of poly(ester–ether–
ester) and of polyurethanes containing poly(ester–ether–
ester) chains were fabricated and tested as devices for the
controlled release of Paclitaxel, an anti-mitotic drug [41].
Some authors studied a low molecular weight and tem-
perature-sensitive hydrogel PVL–POE–PVL with vascular
endothelial growth factor (VEGF) for the controlled local
release of the cytokine [42].
The cardiac ECM plays a fundamental role in wound
repair post-myocardial infarction and its degradation and
remodelling is controlled by matrix metalloproteinase
(MMPs) proteolytic system. Cardiac tissue repair following
MI is a complex process involving three overlapping pha-
ses: inflammation process, granulation tissue formation and
late remodelling that can ultimately lead to a progressive
decline of heart contractile function. Specific spatial and
temporal profiles of MMPs and their inhibitors (TIMPs)
were described for each of these phases [43]. In particular,
the MMP-9 is over-expressed and its active form increases
mainly during the first and second phase in infarcted
myocardium. Activation of MMP-9 can stimulate detri-
mental effects on the healing process while the TIMPs
expression, participating in the maintenance of normal
cardiac functional integrity, seems to be reduced following
MI. Studies on animal models have demonstrated the effi-
cacy of some pharmacological agents (such as ramapril,
valsartan, propanolol) in modulating the MMPs/TIMPs
balance [44]. However, the main challenge is to target a
specific element among the broad spectrum of different
enzymes belonging to the MMP family [43]. In this context,
our idea was to evaluate the possibility of using the MI
technology to obtain a potential therapeutic tool, innovative
in respect to the existing chemical agents, able to recognize
selectively a specific MMP at a particular time step.
With the aim of developing new biodegradable multi-
functional scaffolds replicating cardiac ECM structure also
reducing or preventing the left ventricle remodelling
[45–48], we planned a framework consisting of different
phases. At first, novel microfabricated systems, composed
of synthetic or bioartificial materials, were prepared and
characterised. This phase consists of three specific tasks:
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(i) synthesis and characterisation of new biodegrad-
able poly(ester–ether–ester) copolymers (PVL–POE–PVL)
obtained by ring-opening mechanism in the complete
absence of catalyst; (ii) processing of copolymer, also in
combination with a biological component, in a ECM-like
microstructure specifically designed for this purpose; (iii)
physicochemical, mechanical, and biological characterisa-
tion of polymeric manufacts. Secondly, microfabricated
systems were modified by adding molecularly imprinted
nanoparticles (MIPs) able to recognize a specific metallo-
proteinase (MMP-9). This phase includes two principal
tasks: (i) synthesis and characterisation of MIPs towards
MMP-9; (ii) deposition of MIPs onto microfabricated
structure surface.
2 Experimental
2.1 Materials
To obtain three-blocks copolymers, d-valerolactone (VL,
Aldrich), and poly(ethylene glycol) standards (Aldrich)
with number-average molecular weight of 20,000 Da
(PEG20k), and 35,000 Da (PEG35k) were used as
reagents. Tin(II) 2-ethylhexanoate (Aldrich) was used as
catalyst for preliminary syntheses. VL was purified to
remove the inhibitor using a packed column containing the
inhibitor remover (Aldrich), then dried in vacuum oven at
low temperature and stored at -20C. PEGs were dried
under-vacuum to remove water content and stored in a
desiccant container at room temperature. Tin(II) 2-ethyl-
hexanoate was used without any further purification.
Gelatine A from porcine skin (GEL, Aldrich) was used
as received to obtain bioartificial materials.
Poly(dimethylsiloxane) prepolymer (Sylgard 184 kit)
was used to prepare the microfabricated mould.
For nanoparticle synthesis, methacrylic acid (MAA,
Sigma Aldrich), poly(ethylene glycol) ethyl ether methac-
rylate ((PEG)EEMA, Sigma Aldrich, average molecular
weight 246 Da) as monomers and thrimethylolpropane
thrimethacrylate (TRIM, Sigma Aldrich) as cross-linker
were used. Monomers were purified and stored with the
same procedure used for VL while TRIM was used as
received. Sodium metabisulfite (Aldrich, Na2S2O5) and
ammonium persulfate (Aldrich, (NH4)2S2O8) were dried
and used as radical initiator of the reaction. Human MMP-9
(92 kDa, R&D Systems Inc.) metalloproteinase enzymes
were used to obtain MIPs.
For MTT test (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide assay), Dulbecco’s modified Eagle’s
medium (DMEM, Cambrex) containing 10% v/v fetal
bovine serum (FBS, Cambrex), C2C12 line cells (European
Collection of Cell Culture), and ELISA reader (BioRad
mod.450) were used.
Dimethylsulfoxide (DMSO), chloroform (CHL), dichlo-
romethane (DCM) methanol (MeOH), ethanol (EtOH),
acetone (ACT), tetrahydrofuran (THF), isopropanol (ISP),
acetonitrile (ACN), hydrochloric acid (HCl) all purchased
from Carlo Erba Reagenti and with HPLC purity degree,
and bidistilled water (Direct-Q UV system, Millipore) were
used as solvents. A phosphate buffered saline (PBS, Sigma)
solution with pH 7.4 was used as reaction medium to
prepare nanoparticles and for degradation tests.
2.2 Synthesis of three-block copolymers
Preliminarily, a series of three-blocks copolymer syntheses
were performed by varying the PEG molecular weight and
the VL/PEG percentage weight ratio (90/10, 85/15, 80/20)
to obtain tunable systems in terms of degradation and
mechanical properties. Syntheses were carried out both in
the presence and in the complete absence of catalyst.
Ring-opening polymerisations in the presence of the
catalyst (0.11% w/w) were performed under dry N2
atmosphere at 100C for 24 h. Reaction products were
purified by repeated precipitation into bidistilled water
from DMSO solution, filtered and dried under-vacuum to
completely remove residual water. Syntheses in the pres-
ence of catalyst were carried out mainly for a rapid and
efficient preliminary evaluation of the newly-synthesised
materials, then polymerisations were performed using a
special reaction apparatus specifically designed for the
synthesis of this kind of copolymers, following a procedure
already optimized in the past by researchers of our group
for analogues copolymers [31–33].
Polymerizations were carried out in glass tubular reac-
tors directly connected to a vacuum line. The line is pro-
vided of a turbo-molecular pump (Oerlikon Leybold
Vacuum) able to reach pressures up to 10-9 mmHg. The
measured volume of VL was dispensed into a glass tube
containing the pre-weighed amount of PEG, the reaction
mixture was connected to the vacuum line for 24 h and
maintained at maximum vacuum (about 10-4 mmHg). The
tube was sealed off using a Swagelok valve and placed in
oven at 100C. After 1 week, the reactor was opened and
the mixture dissolved in CHL. Products were quantitatively
recovered by precipitation in excess of MeOH, washed
several times with aqueous MeOH and dried in vacuum at
37C. Under-vacuum syntheses were carried out three
times for each material in order to evaluate the repeat-
ability of the preparation. Preliminary Fourier-transform
infrared (FT-IR) and differential scanning calorimetry
(DSC) analyses were performed onto obtained products
showing no differences in the results.
J Mater Sci: Mater Med
123
2.3 Preparation of cardiac ECM-like microfabricated
polymeric systems
In this work, a rectangular cell configuration mimicking
cardiac ECM for fabrication of scaffolds was used (Fig. 1).
The design of the geometry, already described in detail in a
previous article [17], was obtained directly from optical
microscope images of transversal and longitudinal sections
of porcine cardiac tissue. Specimens of the tissue, both
decellularized and not, were embedded in paraffin and
sectioned by rotary microtome for staining. From tissue
cross sections, micrometric parameters were obtained
(cardiomyocyte dimensions and thickness of connective
tissue surrounding bundles of muscle fibres). On the basis
of this evaluation, the micro-pattern model, well fitting the
cardiac ECM geometry and simple to be transferred to
microfabrication techniques, is characterised by rectangu-
lar cavities (500 lm 9 100 lm), able to hypothetically
locate 2–3 cardiomyocytes. The meshed structure also
presents thick lines of 30 and 70 lm corresponding to
different contents of connective tissue components (mainly
collagen I).
The 2D CAD model of the geometry was obtained using
SolidWorks (Dassault Syste`mes, SolidWorks Corp.).
Master geometry was obtained through the soft lithography
technique, reproducing the single-cell geometry to generate
a micro-patterned scaffold with 5 cm 9 2.5 cm in dimen-
sion, suitable for a wide range of characterisations (i.e.,
bioreactor). A poly(dimethylsiloxane) mould was pro-
duced, following the standard procedure indicated for the
Sylgard kit. Mould was detached from the master and used
as substrate for the deposition of the polymeric solution.
Different polymeric solutions composed of copolymer or
bioartificial blends were prepared. Microfabricated systems
of pure PVL–POE–PVL, were obtained pouring 1 ± 0.2 ml
of polymeric solution in CHL (15% w/v) using a micropi-
pette. Solutions were spread onto the mould and the excess
of solution was removed to obtain thin and porous structures
by casting of the solvent in a vented oven at controlled
temperature (40C for 2 h). The complete removal of the
organic solvent was verified by FT-IR analysis.
Microfabricated bioartificial systems were obtained by
phase inversion for controlled casting from a ternary sol-
vent blend composed of a solution of PVL–POE–PVL in
DCM (20% w/v), ACT and a solution of GEL in water
(10% w/v). The percentage volumetric composition of the
solvent mixture was 52/42/6, respectively. The bioartificial
blend PVL–POE–PVL/GEL (90/10 w/w) was homoge-
neously distributed over the PDMS mould and casted at
35C in vented oven. Microfabricated materials obtained
were gently detached at the end of the casting procedure.
2.4 Characterisation of microfabricated systems
2.4.1 Morphological and physicochemical analyses
Morphological analysis was carried out onto samples
coated with 24 k gold in a vacuum chamber through
scanning electron microscope (SEM) using a JEOL T-300
instrument.
Differential scanning calorimetry was carried out in dry
state in triplicate with a DSC7 apparatus (Perkin Elmer).
Samples (579 mg) were sealed in aluminium pans and
analysed in the temperature range from -30 to 150C
under N2 flux (temperature ramp 10C/min). PVL–POE–
PVL, PEG35k standard, homopolymer PVL, a mechanical
blend PVL/PEG in the form of thin films obtained by
casting were analysed.
Gel permeation chromatography (GPC) was performed
to evaluate macromolecular compositions and molecular
weights of the products using a Perkin Elmer series 200
apparatus equipped by refractive index and UV detector
(k = 245 nm), a ResiPore column (300 9 7.5 mm, parti-
cle size 3 lm) with THF as mobile phase (flow 1 ml/min).
Samples were dissolved in CHL (0.2% w/v) and mea-
surements were acquired on the basis of a calibration curve
obtained from polystyrene standards dissolved in CHL and
the TurboSec software (PerkinElmer).
Fig. 1 Design of the ECM-like
structure of the microfabricated
polymeric systems: a simplified
geometric scheme of a single-
cell of the structure with
dimensions; b hypothetical
cardiomyocytes arrangement
within cells; c superposition of
the designed ECM-like structure
on the native cardiac tissue
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Total reflection FT-IR spectra were obtained through
Spectrum One FT-IR Spectrometer (Perkin Elmer). Sam-
ples of copolymers obtained both in the presence and in
absence of catalyst and samples of corresponding homo-
polymers were analysed to verify the presence of charac-
teristic peaks of the components.
2.4.2 Mechanical characterisation
Mechanical properties were evaluated by DMA 8000
(Perkin Elmer). A set of mechanical analyses (tensile,
strain scan and multi-frequency tests) was carried out to
evaluate elastic modulus and complex dynamic modulus in
strain and in multi-frequency scans. Quasi-static tensile
tests were performed with 0.01 s-1 strain rate; strain scan
tests were performed applying a stepped strain (from
0.01% to 30%) in 0.01 s per step; multi-frequency tests
were performed on pre-deformed samples (5% in respect to
the starting length) by applying a cyclic strain (10%
referred to the pre-strain) at three different frequencies
(1, 2, 3 Hz). Tests were carried out in triplicate.
2.4.3 Degradation tests
Degradation tests were carried out in triplicate by
immersing in PBS microfabricated specimens of pure
copolymers and bioartificial materials. Samples were
maintained at 37C under gentle mechanical stirring. After
6, 12, 30, 40, 50 days samples were removed from the
solution, rinsed with distilled water, dried, and weighed.
The extent of degradation was calculated according to
Eq. 1
wL ¼ w0  w tð Þ
w0
 100 ð1Þ
where wL is residual weight percentage, w0 is the starting
dried weight and w(t) is the dried weight of the sample after
degradation.
2.4.4 Sterilization and cytotoxicity tests
Sterilization tests were performed onto three samples for
each typology of microfabricated systems to evaluate the
stability of materials after sterilization procedure. Squared
samples (1 cm 9 1 cm) were immersed in the sterilization
medium (70% EtOH aqueous solution) for 30 min by
changing the medium after 15 min. Then, samples were
dried and placed under UV light for 15 min on each sample
side to complete the sterilization procedure. Finally, sam-
ples were weighed to evaluate the loss in weight following
sterilization.
Preliminary cell viability tests were performed by means
of MTT assay on microfabricated samples obtained by pure
copolymers and bioartificial systems. Samples (1 cm 9
1 cm) were sterilised as described. Microfabricated sys-
tems were placed in 24-well plates and seeded with a
C2C12 cell suspension (cell density 105 cells/ml) in
DMEM containing FBS. Cells were also cultured directly
on the wells as control. Cell culture was carried out in a
humidified atmosphere containing 5% CO2 at 37C for
72 h. After 24 and 72 h of incubation, cell viability was
measured by MTT assay as follows. After each time, MTT
(1 mg/ml in PBS) was added to the medium in volumetric
ratio 1:10 and samples were further incubated for 4 h at
37C. The medium was removed and purple formazan
crystals were solubilized with 200 ml of acidic ISP
(0.04 M HCl in ISP) at room temperature. Optical density
(OD) at a k = 570 nm was determined using an ELISA
reader. In order to carry out a statistical analysis
(ANOVA), seven tests were performed onto bioartifi-
cial blends in form of membrane and microfabricated
structure.
2.5 Synthesis of imprinted nanoparticles
towards MMP-9 (MMP-9/MIPs)
Molecularly imprinted nanoparticles able to recognize
MMP-9 were synthesised using precipitation polymerisa-
tion method. The synthesis was performed by radical
polymerisation of MAA and (PEG)EEMA in the presence
of TRIM. Human MMP-9 (total), also known as gelatinase
B and secreted as a 92 kDa zymogen, was also added in the
reaction feed.
The template molecule (MMP-9) (40 ng) was suspended
in PBS solution by adding 1 ml into the vial and mix
gently. MAA and (PEG)EEMA (percentage molar ratio
MAA/(PEG)EEMA 75/25), TRIM (20% mol/mol in
respect to the total amount of monomers) were inserted in
reaction tube and mixed at 37C. Thereafter, the MMP-9
solution was added into tube reactor containing reagents,
operating under dry N2 flux and maintaining reaction mass
at 37C. When the solution became clear, 0.05 M of
Na2S2O5 and (NH4)2S2O8 already dissolved in PBS (1 ml)
at 37C were added to the solution under agitation. Tube
reactor was sealed off and the polymerisation was carried
out for 3 h ensuring a light constant stirring at 37C. The
solid product obtained in form of nanoparticles was sepa-
rated by the PBS solution by ultracentrifugation (Mikro
200 Hettich Zentrifugen) with 14,000 rpm for 15 min.
Then, nanoparticles were washed by bidistilled water for
three times and dried in vented oven at 37C. The template
enzyme was removed by several washing in PBS solu-
tion; at each extraction cycle nanoparticles suspension was
ultracentrifuged and supernatant withdrawn and collect to
successive HPLC analysis in order to determine amount of
MMP-9 extracted. Not-imprinted nanoparticles (CPs) were
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prepared as control in the absence of MMP-9 and treated in
the same way.
2.6 Characterisation methods of MMP-9/MIPs
2.6.1 Recognition experiments
To evaluate the binding capacity of MMP-9 imprinted
nanoparticles (MMP-9/MIPs), 30 mg of MIPs or CPs were
placed in eppendorf and incubated in 1 ml of rebinding
solution (10 ng of MMP-9 in 1 ml of PBS) under gentle
agitation at 25C for 2 h. MIPs and CPs suspensions were
ultracentrifuged and supernatant withdrawn from each ep-
pendorf was analysed by HPLC to evaluate the residual
amount of MMP-9 in both cases. To determine MMP-9
amount both in extraction and rebinding solutions, a C18-
Synergy Hydro-RP (250 9 3 mm, 4 lm, Phenomenex)
column was used, ACN/water (80/20 v/v) as mobile phase
(flow rate 0.8 ml/min), UV detector was set at 280 nm and
injections were performed autosampling 10 ll of different
solutions.
A series of parameters were calculated as indicated in
following equations:
MMP-9retained ¼ ng MMP-9final
ng MMP-9initial
 100 ð2Þ
MMP-9extracted ¼ ng MMP-9extracted
ng MMP-9retained
ð3Þ
Rebinding capacity
¼ MMP9bound by MIP  MMp-9bound by CP
Nanograms of MMP-9retained
 100
ð4Þ
Specific rebinding
¼ ng MMP-9bounnd by MIP  MMp-9bound by CP
Grams of polymer
ð5Þ
Recognition tests were performed onto three series of
nanoparticles obtained in three different syntheses. For
each product, tests were performed in triplicate and then
results following reported are mean values of nine different
tests. However, no relevant differences were detected
between products obtained in different syntheses.
2.6.2 Zymography analysis
To evaluate the activity of MMP-9 after rebinding tests, the
zymography assay of rebinding solutions after contact with
MIPs and CPs was performed. MMP activity in different
enzyme solutions was analysed using gelatin zymogra-
phy, performed by standard procedures using a sodium
dodecylsulfate/polyacrylamide gel electrophoresis matrix
containing gelatin (1 mg/ml). The activity of the bands was
quantified by densitometry (ImageQuant, Molecular
Dynamics). The zymograms were analysed for a lytic band
corresponding to standards for the proenzyme (92 kDa)
form of MMP-9. The values obtained for MMP activity for
each sample were normalized for their protein concentra-
tion using HPLC assay. Tests were performed in triplicate.
Once normalized, results of MMP-9 activity in solutions in
contact with MIPs and CPs were compared.
2.7 Biofunctionalisation of MMP-9/MIPs
on microfabricated systems
MMP-9/MIPs spray deposition onto microfabricated sys-
tems was optimized to avoid any alteration of the poly-
meric structure. Particles were grinded, dispersed in EtOH
aqueous solution (70% v/v) and sonicated with a Ultrasonic
06 apparatus (Falc) for 30 min, then were mechanical
stirred and nebulisated on both sides of the microfabricated
system. Finally, systems were exsiccated at 25C.
After the nanoparticle deposition, the MIPs-modified
microfabricated biodegradable systems were subjected to
stability tests in order to verify the MIPs adhesion. Samples
were immersed in PBS solution and maintained under
stirring for 3 days, then dried and analysed by SEM.
3 Results and discussion
3.1 Synthesis of three-blocks copolymers
and characterisations
Six different copolymers, obtained by varying the length of
the PEG chain and the weight ratio between components,
were obtained in the presence of catalyst. At first, pro-
cessability was verified. Copolymers with VL/PEG ratios
80/20 and 90/10 showed that it was not possible to obtain
consistent and reproducible products. For this reason, these
compositions were not considered for further tests. On the
contrary, copolymers with composition 85/15 obtained
with both PEGs were well processed into thin films and
preliminarily characterised. On the basis of this aspect, the
synthesis in absence of catalyst was carried out only for
copolymers with composition 85/15.
In Table 1 results of tensile tests and in vitro degrada-
tion analysis onto copolymers PVL–POE–PVL 85/15,
obtained using both PEG20k and PEG35sk, are reported.
Elastic modulus of materials containing PEG35k were
smaller than those obtained with materials containing
PEG20k, resulting more similar to mechanical values
reported in literature for myocardial native tissue [13]. In
addition, stability in PBS of copolymers with PEG35k was
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significantly higher than those containing PEG20k, inde-
pendently by the presence of the catalyst in the reaction
feed. For this reason, further characterisations were carried
out only onto copolymers containing PEG35k (copolymer
obtained in the presence of the catalyst was considered
only as reference system).
Fourier-transform infrared spectra of the copolymer
showed the presence of the typical bands of PVL and PEG
homopolymers (stretching of C=O at 1,723 cm-1 and
stretching mode of C–O at 1,165 cm-1 typical of PVL;
stretching of C–O–C at 1,065 cm-1 typical of PEG), con-
firming for each of them their ester-ether structure (Fig. 2a).
DSC thermograms for copolymers, homopolymers (PVL
and PEG35k) and a mechanical blend (85/15 w/w) are
reported in Fig. 2b. In the trace of the mechanical blend, the
presence of two distinct peaks at the same temperatures was
observed, corresponding to melting of pure homopolymers.
On the contrary, for copolymers only one melting event was
registered, indicating that the copolymerisation occurred. A
decrease in the melting temperature for copolymers in
respect of homopolymers was observed, in agreement with
results obtained for similar block copolymers as reported in
literature [31–33]. Considering the melting enthalpy, a
reduction of the values was observed for copolymers (96
and 102 J/g for catalysed and not-catalysed respectively
versus 150 J/g for PVL and 280 J/g for PEG35k). This
result could be explained with the hypothesis that the seg-
ment that crystallises first (PVL) has a tendency to freeze
the whole structure, thus imposing either imperfect crys-
tallization or smaller crystallites onto the POE segment.
Tests were performed in dry state but a more exhaustive
characterisation in wet conditions maybe necessary, as
suggested in the work of Zeugolis and Raghunath [49].
Gel permeation chromatography analysis showed that
the weight average molecular weight of the copolymer
obtained both in catalysed and in uncatalysed reaction was
similar (1.45 9 105 and 1.42 9 105 Da, respectively). In
addition, the macromolecular composition was evaluated
(VL/PEG35k weight ratios were found to be 76/24 and
75/25, respectively). This result allows evaluating the VL
conversion at the end of the reaction (89.4 and 88.2%,
respectively), confirming that the under-vacuum reaction
scheme designed ad hoc showed a great efficiency.
Considering that the physicochemical behaviour of
copolymers obtained through both reaction schemes did
not show substantial differences, bioartificial materials
were prepared using the copolymer obtained in the absence
of catalyst. It ensures a greater biocompatibility of the final
product, considering that traces of toxic catalyst could
persist also after a deep purification.
DMA tests allowed evaluating mechanical properties of
the materials. Elastic modulus obtained in tensile tests were
already reported in Table 1 and discussed. Results of
dynamic tests are summarised in Fig. 3. In multi-frequency
tests (Fig. 3a), E0 did not show significant differences by
varying the frequency, both for synthetic and bioartificial
samples. Results of E00 are not reported, however, values
were found to be very low in respect of E0, indicating a
predominant elastic behaviour. Storage modulus resulted in
the order of MPa for copolymer samples, with values
Table 1 Elastic modulus evaluated through tensile tests for copoly-
mers with VL/PEG percentage ratio 85/15 obtained both with cata-
lysed and not-catalysed synthesis
Copolymer Catalyst Elastic
modulus
(MPa)
wL (Eq. 1)
PVL–POE–PVL 85/15
(PEG20k)
Yes 65.8 ± 1.2 20.5 ± 1.1
No 52.4 ± 2.5 24.1 ± 1.2
PVL–POE–PVL 85/15
(PEG35k)
Yes 9.1 ± 0.3 8.1 ± 0.6
No 9.0 ± 0.1 8.2 ± 0.8
%
T
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
PEG35k
PVL
(a) (b)
PVL-POE-PVL catalysed
PVL-POE-PVL not catalysed
PEG35k
PVL
PVL-POE-PVL catalysed
PVL-POE-PVL not catalysed
Mechanical blend
Fig. 2 Physicochemical characterisation: a FT-IR spectra of copoly-
mers 85/15 obtained with and without catalyst compared with spectra
of homopolymers and b DSC second scan thermograms, obtained in
dry conditions, of copolymers 85/15 compared with thermograms of
homopolymers and mechanical blend (85/15 weight composition),
scan rate 10C/min
J Mater Sci: Mater Med
123
similar to the native cardiac tissue [46]. For bioartificial
specimens higher values were registered (68.4 ±
1.0 MPa). Strain scan analysis (Fig. 3b) confirmed the
previous results. In both tests, the bioartificial system
showed higher values of E0 than the pure copolymer.
However, results are compatible with specific application
considering that measurements were performed in the dried
state rather than in aqueous conditions.
Differential scanning calorimetry analysis was carried
out onto the bioartificial system containing GEL (10% w/w
in respect to the synthetic polymer content). Thermograms
of the pure copolymer and of the bioartificial system did
not show significant differences (melting enthalpies were
102 and 99 J/g, respectively, melting temperatures were 51
and 57C).
Another important aspect of this work was the design
and fabrication of scaffolds with rectangular-meshed con-
figuration approximating cardiac ECM geometry. In Fig. 4
the microstructure obtained by soft lithography for the
scaffold based on PVL–POE–PVL copolymer shows a high
correspondence with the predefined geometry. The accu-
racy of replication is confirmed by the measured values of
the cell profiles (490 ± 5, 99 ± 3, 71 ± 2, and 35 ±
2 lm) that are very similar to the geometry of the model
used (500, 100, 70, and 30 lm).
To evaluate the kinetics of in vitro degradation between
microfabricated systems based on pure copolymer and
those based on PVL–POE–PVL/GEL blend, mass loss of
both materials after incubation in PBS solution was eval-
uated up to 40 days. For both systems, a constant and
gradual weight reduction was observed although bioartifi-
cial systems showed a faster degradation rate as compared
to pure copolymer systems (Fig. 5a). After 40 days,
microfabricated samples of pure copolymer showed 10%
mass loss while a value of mass loss of 37% was registered
for bioartificial structure. The higher degradation rate for
bioartificial materials have to be rationally ascribed to a
release, even is gradual, of GEL component during deg-
radation time.
The evaluation of the mass loss after sterilization was
carried out and not significant decrease in the sample
weights were detected, for both synthetic and bioartificial
materials, resulting smaller than 2%.
Preliminary studies of cytocompatibility on materials
obtained were performed. As the most significant example
of in vitro cell culture results, absorbance values measured
by MTT tests (Fig. 5b) for a microfabricated bioartificial
system were compared with those obtained with a material
having the same chemical composition (PVL–POE–PVL/
GEL 90/10 w/w) but not microfabricated. Both systems did
(b)(a)
0
10
20
30
40
50
60
70
Synthetic material Bioartificial material
E'
 [M
Pa
]
0
10
20
30
40
50
60
70
80
1 Hz 2 Hz 3 Hz
E'
 [M
Pa
]
Synthetic material Bioartificial material
Fig. 3 Results of mechanical analysis onto copolymer 85/15
obtained through under-vacuum synthesis and the respective bioar-
tificial blend: storage modulus (E0) a obtained in multi-frequency tests
(pre-strain 5% and cyclic strain 10% on the pre-strain value) and b in
strain scan tests (stepped strain from 0.01 to 30% in 0.01 s per step);
values represent the mean (n = 3) ± STD
490 5 µm
99 3 µm
35 2µm
71 2 µm
(a)
(b)
(c)
Fig. 4 Microfabrication: a the
Teflon container where the
silica master (5 cm 9 2 cm)
used to prepare silicon moulds
was stuck; b SEM image of the
PDMS mould used to prepare
samples; and c SEM image of
the microfabricated system
surface for PVL–POE–PVL
85/15, obtained through under-
vacuum synthesis and particular
of a single-cell of the structure
with line dimensions
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not show significant effects on the cytotoxicity (P \ 0.05).
However, cell viability measured after 72 h respect to
negative control was 70% (P \ 0.05) for not microfabri-
cated materials and 90% (P \ 0.05) for the microfabricated
system. Such important result seems to suggest a positive
effect of anisotropic structure of the polymeric material on
cell viability.
3.2 Synthesis and characterisation of MIPs
A crucial objective of this work was to develop a scaffold
addressing an important strategy of therapies in human
cardiology to restore the correct equilibrium MMPs/TIMPs.
Towards this goal, we thought to apply MI technology for
the production of nanoparticles able to remove, in a con-
trolled extent, MMP-9 involved in the early adverse phases
of cardiac repair. The presence of complementary nanosites
on the particle structure should ensure a high-selective
removal, not involving other molecules or enzymes present
in the cardiac microenvironment. The synthesis of nano-
particles was carried out selecting two monomers, MAA
and (PEG)EEMA, the first because is well known efficient
monomer in MI [50], the second because contains a short
chain of PEG exposed able to prevent inflammatory reac-
tions and removal by RES. In addition, synthesis was per-
formed using two catalysts that permit to carry out the
reaction at 37C and for 3 h, with the benefit of preserving
as much as possible the bioactivity of the enzyme.
Concerning the characterisation of MIPs imprinted with
MMP-9, carried out by HPLC, the amount of the MMP-9
contained in the final product, calculated as the difference
between the amounts contained initially and the content
found in reaction mixture, is reported in Table 2 as per-
centage of entrapped enzyme according to the equations
indicated in experimental section. MMP-9/MIPs exhibited a
good capability of entrapping the template molecule,
resulting in 56.95% encapsulation efficiency. Since high
cost and low availability of these enzymes, this result
underlines the effectiveness of the followed experimental
strategy. In the same table, the quantitative extraction of
enzyme by repetitive PBS washing is reported as extracted
fraction and the resulting value was 1.15%. As expected for
MI of proteins [51], a permanent entrapment of the template
in the polymer matrix, due to physical/chemical immobili-
zation, occurred. A limited removal of biomacromolecule
template was found but, for this specific application, this
value can be considered acceptable. In fact, basing on the
results reported in literature, a template removal from 50 up
to 95% can be achieved for some proteins, but these effi-
ciency levels are crucial mainly for conventional applica-
tions of MI such as analytical separations, enzyme-like
catalysis or chemical sensors [21–23, 50].
Rebinding test was performed using an enzymatic solution
with concentration 10 ng/ml (3.3 9 10-4 mg/g nanoparti-
cles), both MIPs and CPs absorb quantitatively MMP-9,
however a significant difference in rebinding behaviour was
observed between, them showing a recognition factor of 1.34.
This result confirms the effectiveness of MI technique to
obtain specific binding sites on nanoparticles. Additionally, a
particularly interesting result originates by the observation
(a) (b)
70%
90%
0,00
0,10
0,20
0,30
0,40
0,50
1 day 3 days
*
*
*
Ctrl Bioartificial not microfabricated system
Bioartificial microfabricated system
Fig. 5 a In vitro degradation test onto the pure copolymer with
composition 85/15 obtained through under-vacuum synthesis and the
respective bioartificial blend (90/10), residual weight of samples after
degradation in PBS solution; b In vitro cell viability using C2C12
cells by MTT assay, comparison between values of absorbance for
PVL–POE–PVL/gelatin (90/10) membranes having micro patterned
surface and not with respect to the tissue culture plate as negative
control (nCtrl), values represent the mean (n = 7) ± SD; ANOVA
test, significance level referred to nCtrl: * P \ 0.05; ** P \ 0.01
Table 2 Characterisation of
MIPs and CPs nanoparticles
Polymeric
nanoparticles
% MMP-9
bound/MMP-9
rebinding
solution
% MMP-9
retained
(Eq. 2)
% MMP-9
extracted
(Eq. 3)
Rebinding
capacity
(Eq. 4)
Specific
rebinding
(Eq. 5)
MIPs 10.40 56.95 1.15 1.15 18.67
CPs 7.80 – – – –
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that the percentage of enzyme extracted corresponds exactly
to the percentage of enzyme rebound (1.15 is the value reg-
istered for both parameters) as indicated in Table 2. This
means that the enzyme was able to occupy all the comple-
mentary specific sites on the MIPs.
Considering that mean values of MMP-9 concentration
measured in rebinding solutions resulted in around 10 ng/
ml, data obtained referred to rebinding capacity would be
in agreement with those reported in literature for plasma
MMP-9 following infarct myocardial (10–50 ng/ml) [52].
In addition, the possibility of using MIPs nanoparticles to
attempt to remove specifically the enzyme correcting the in
vivo MMP/TIMPS balance seem to be confirmed by these
first experimental data. In particular, low percentage of
enzyme rebinding represents a desirable result since the
removal of high amount of enzyme in the microenvironment
could actually be deleterious causing excessive depletion of
enzymes responsible for the ECM cardiac regulation.
The activity of MMP-9 in different aqueous solutions
was determined by zymography analysis. Washing solu-
tions after polymerisation, extraction solutions and rebind-
ing solutions both for MIPs and CPs were analysed and
corresponding results were reported in Fig. 6. No evidence
of activity was detected for the enzyme present in washing
and extraction solutions (test tube indicated with 1, 2, 3, 4,
in Fig. 6), reasonably due to drastic treatments that were
carried out on nanoparticles imprinted with MMP-9. But a
significant result was obtained comparing the evaluated OD
of rebinding solutions after incubation with MIPs and CPs
(test tube indicated with 5 and 6 in Fig. 6). MMP-9 activity
normalized by enzyme content in rebinding solution was
4.20 for CPs and 14.83 for MIPs. These values were
quantified using two independent assays, determining OD
by zymography assay and enzyme concentration by HPLC.
In most papers, enzyme concentration is quantified by direct
ELISA measurements using standards curve, however the
use of distinct methods is preferable and strengthens
validity and accuracy of results obtained. The activity of
MMP-9 measured in the solution after contact with
imprinted nanoparticles was approximately 3.5 times higher
than with not-imprinted particles. It could be explained with
the previous contact of enzyme with MIPs structure that
affected not only the amount of enzyme rebound but also its
conformational state that determines its biological activity.
3.3 Biofunctionalisation of MMP-9 imprinted
nanoparticles on microfabricated systems
Finally, in order to functionalize the microfabricated system
by combination with MMP-9/MIPs, a procedure of deposi-
tion of nanoparticles onto the matrix was followed, as
described in the experimental part. The choice of the solvent
used to spread MIPs on the microfabricated system is critical
to achieve a permanent physical immobilization until this
will not degrade and nanoparticles will be cleared by
physiological fluids. EtOH proved to be the most appropri-
ate, as confirmed by SEM analysis and stability test. SEM
image of scaffold after modification shows no alteration of
the structure, in particular the rectangular-patterned surface
is maintained (Fig. 7a). In addition, SEM analysis of
microfabricated scaffold after stability test in aqueous
environment allows ascertaining the efficacy of deposition
procedure optimized (Fig. 7b). In particular, the solvent
used allows a stable linking between nanoparticles and
Fig. 6 Results of zymography analysis, evaluation of the OD for
tested samples; standards are indicated as St.x, samples indicated with
5 and 6 are solutions withdrawn after rebinding tests for CP and
MMP-9/MIP, respectively; no protease activity was visualised for CP
(as control) and MIP polymerisation (lanes 1 and 2) and extraction
solutions (lanes 3 and 4)
Fig. 7 Morphological analysis
of the particle-loaded system
obtained through SEM: surface
of the system a after the MMP-
9/MIP deposition and b after
stability tests in PBS solution
for 3 days
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scaffold. It is important to underline that the effect of MMP-
9 occurs mainly in the early remodelling phase (7–21 days)
following infarction, while its role decreases in long term
where MMP-9 returns to basal levels. Consequently, a loss
of MMP-9/TIMP control, triggered by MIPs and due to
degradation of scaffold supporting MIPs in a later stage, can
be considered a desirable result for this specific application.
In addition, morphological analysis of the multi-functional
system showed the presence and distribution of nanoparti-
cles both on the lines and on rectangular cavities. Different
levels of particle aggregation were also found even if the
nanosphere morphology is evident resulting in an approxi-
mately average diameter of 30 ± 10 nm.
On the basis of the results obtained by rebinding test
previously discussed, the amount of MMP-9 rebound was
4.4 9 10-3 ng/cm2 of scaffold surface. Although further
study will be necessary to examine the entity MMP-9
inhibition in quantitative terms, values obtained by re-
binding results seem to be compatible with low levels of
these enzymes in a tissue.
These first results encourage us to continue in the
direction of optimizing the production and characterisation
of MIPs/scaffold systems in view of a future clinical utility
in preventing dysfunction after myocardial infarction.
However, a more extensive study of both the biological
mechanisms involved in the activity of MMP/TIMP and
therapeutic doses/activity are needed to make imprinting
methodology from a simple proof of concept to a concrete
therapeutic tool.
4 Conclusion and future developments
In this work it has been demonstrated the feasibility of
manufacturing new multi-functional systems with a spe-
cific function at meso-, micro- and nano-scale level for
cardiac tissue engineering.
However, for each level, further studies will be neces-
sary to evaluate the efficacy of multi-functional systems
obtained. Currently, the study of effects of only morphol-
ogy functionalisation of the microstructures on the ability
of stem cell differentiation in cardiac sense is underway,
using in vitro cell cultures.
Moreover, recognition experiments on nanoparticles
imprinted with MMP-9 demonstrated the specificity of these
nanostructures towards the enzyme but a further aspect that
is the evaluation of selectivity of imprinted nanoparticles
toward TIMPs and other MMPs has to be performed yet.
Afterwards, 3D multi-layer scaffolds will be prepared by
assembling of two or more microfabricated systems to
achieve the requirements, also in terms of thickness, of an
in vitro engineered myocardial tissue. Dynamic cell culture
tests using a suitable bioreactor will be carried out to
evaluate the effect of mechanical and electrical stimuli on
the formation of construct.
In addition, the possibility to use the 3D multi-layer
scaffolds for in vivo engineered myocardial tissue will be
also evaluated after performing their biofunctionalisation
with specific recruitment factors (e.g., SDF-1a).
Finally, in vivo experiments will allow evaluating the
efficacy of multi-functional systems with synergic effect in
both preventing left ventricular dysfunction and stimulate
new cardiac tissue formation.
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